Effects of Canagliflozin on C-peptide Clearance in Healthy Volunteers
- Sponsor
- Janssen-Cilag International NV
- Study ID
- NCT01665638
- Phase
- PHASE1
- Status
- Completed
Conditions
- Healthy
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 55 Years
- Healthy Volunteers
- Accepted
Interventions
- Canagliflozin 300 mg — DRUGSinge over-encapsulated 300 mg tablet of canagliflozin administered orally (by mouth) on Day 1 of Treatment Period 1 or Day 1 of Treatment Period 2.
- Placebo — DRUGSinge capsule of placebo administered orally (by mouth) on Day 1 of Treatment Period 1 or Day 1 of Treatment Period 2.
- Somatostatin — DRUGA primed (50 mcg in 1 mL sterile 0.9% NaCl solution i.v. injection over 1 minute) constant (500 mcg/hour) i.v. infusion of somatostatin for 4 hours approximately 2 hours after canagliflozin or placebo dosing on Day 1 of Treatment Period 1 and Day 1 of Treatment Period 2. The total dose of somatostatin administered during each period will be 50 mcg + 500 mcg/hour x 4 hours = 2050 mcg.
- C-peptide — DRUGSingle bolus dose of 150 mcg synthetic human C-peptide in 1 mL water for injection administered i.v. (in the vein) approximately 3 hours after canagliflozin or placebo dosing on Day 1 of Treatment Period 1 and Day 1 of Treatment Period 2.
Study Details
The purpose of this study is to assess whether treatment with a single oral 300 mg dose of canagliflozin alters the kinetics (ie, clearance/removal from body) of serum C-peptide (a protein released from the pancreas during insulin secretion) in healthy adult volunteers.
Key Dates
- Start date
- Sep 30, 2012
- Status verified
- Jun 2013
- Primary completion
- Oct 31, 2012
- Completion
- Oct 31, 2012
Study Design
- Enrollment
- 10 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- CROSSOVER
Arms
- Experimental: Treatment Sequence Group AB
- Experimental: Treatment Sequence Group BA
Primary Outcome Measure
Change from baseline in C-peptide kinetic parameters [ Time Frame: Before and after study drug administration on Day 1 of Treatment Periods 1 and 2 ]
Related Studies
- Study of New Magnetic Resonance Imaging Methods of the BrainRecruiting · National Institute of Neurological Disorders and Stroke (NINDS) · Bethesda, Maryland
- Mapping Auricular Vagus Nerve CircuitryEARLY_PHASE1 · Recruiting · Massachusetts General Hospital · Boston, Massachusetts
- Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group TestingRecruiting · Cedars-Sinai Medical Center · Los Angeles, California
- Evaluation and Optimization of Ultrasound and/or MRI Hardware and SoftwareRecruiting · State University of New York - Upstate Medical University · Syracuse, New York